300702.SZ
天宇股份
SZSE · Healthcare · C 制造业 · CN
CNY 21.48
−2.50%Sep 4, 2026, 10:46 UTC
Tianyu Pharmaceutical's wholly-owned subsidiary Zhejiang Jingsheng Pharmaceutical's sitagliptin phosphate API passed the review by China's Center for Drug Evaluation (CDE).
Source:Aug 27, 2026, 08:43 UTC
Tianyu Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 104 million yuan, down 32.12% year-on-year, with revenue of 2.011 billion yuan, up 13.23%.
Source:Aug 6, 2026, 08:36 UTC
Tianyu Co., Ltd.'s wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. received the drug registration certificate for Vardenafil Hydrochloride Tablets approved by the National Medical Products Administration, with a specification of 10mg, registration classification as chemical drug category 4, approval number Guoyao Zhunzi H20265478, valid until August 3, 2031, for the treatment of male erectile dysfunction.
Source:Aug 4, 2026, 08:31 UTC
Tianyu Pharmaceutical's subsidiary Zhejiang Nuode Pharmaceutical was selected in the 12th national centralized drug procurement for two products, with the procurement period running until December 31, 2029.
Source:Jul 2, 2026, 06:59 UTC
India's Ministry of Commerce and Industry issued a final affirmative anti-dumping ruling on 4-bromomethyl-2'-cyanobiphenyl originating in or imported from China, recommending a five-year anti-dumping duty of $5,089–$6,305 per tonne.